Related Experiment Videos
What's in a Name? Cell Fate Reprogramming in Sarcomagenesis
1Departments of Orthopaedics and Oncological Sciences, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Drive, Room 3726, Salt Lake City, UT 84112, USA.
Cancer Cell
|January 10, 2018
Summary
Cancer cells can change their identity through transdifferentiation. A single oncogene activated in endothelial cells can reprogram them to develop rhabdomyosarcoma, a cancer with muscle features.
Area of Science:
- Oncology
- Developmental Biology
- Cell Biology
Background:
- Cancer cell differentiation is generally linked to the cell type from which the cancer originated.
- Understanding the plasticity of cancer cell identity is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the potential for cell fate reprogramming in cancer development.
- To identify the mechanisms driving the apparent transdifferentiation in rhabdomyosarcomas.
Main Methods:
- Utilized a model system involving endothelial cell precursors.
- Introduced a single oncogene to trigger cell fate changes.
- Analyzed the resulting cellular characteristics and differentiation markers.
Main Results:
- Demonstrated that activation of a single oncogene in endothelial cell precursors can induce a transdifferentiation program.
- Observed the emergence of rhabdomyosarcoma, a cancer exhibiting skeletal muscle differentiation features.
- Provided evidence for cell fate reprogramming as a mechanism in oncogenesis.
Conclusions:
- Cancer cell differentiation features are not solely determined by the cell of origin.
- Oncogene activation can induce significant cell fate reprogramming, leading to distinct cancer types.
- This study reveals a novel pathway for rhabdomyosarcoma development through endothelial cell transdifferentiation.